InflaRx Plans Two 2027 Izicopan Vasculitis Trials, Sees $1.5 - 2.0 Billion Peak Sales Potential
The company's own research puts peak sales potential at $1.5 - 2.0 billion, and it says €153.3 million in cash lasts through 2029.
InflaRx, the Jena, Germany-based company that develops drugs blocking the immune protein C5a or its receptor, said Tuesday it intends to start two Phase 2 trials of its pill izicopan in ANCA-associated vasculitis (AAV) in 2027, with first data anticipated in 2028. At its Capital Markets Day, the company also said its own research points to peak sales potential of $1.5 - 2.0 billion.
Two trials, two different questions
The first study is randomized, double-blind and placebo-controlled, in AAV patients with kidney involvement. Site initiation is expected in early 2027. It tests two izicopan doses on top of standard care, including rituximab and a steroid taper, with about 35 patients per arm, 12 months of treatment and key readouts at 24 weeks. Enrollment is planned to take about 18 months.
The second is an open-label study in newly diagnosed or relapsing patients needing remission-inducing therapy. It uses two stages: a rapid glucocorticoid (steroid) taper first, then, once safety is assessed, a planned complete replacement of the steroid. First data are expected in 2028.
The company said that study draws on a Phase 1/2 trial of BDB-001, an antibody targeting C5a licensed to its Chinese partner Staidson BioPharmaceuticals, in which complete steroid replacement at enrollment produced numerically favorable remission rates against an open-label control arm. InflaRx does not expect running both trials at once to slow enrollment, citing different enrollment criteria and separate centers.
The placebo-controlled design was informed by first interactions with the FDA, the company said, and it continues to look for the fastest route into a registration-stage trial.
A $1.5 - 2.0 billion estimate, and who made it
InflaRx said its proprietary research indicates izicopan could significantly expand the AAV market, with estimated peak sales potential of $1.5 - 2.0 billion, based on an independent commercial assessment. The company says the pill could offer faster and deeper target inhibition, more convenient dosing and a better safety profile. It reports no safety signals of concern among the 197 people dosed so far.
CEO Niels Riedemann said C5aR inhibition "has been clinically and commercially validated," and that izicopan was built to extend that foundation.
Cash through 2029, and other readouts
Cash, cash equivalents and marketable securities came to €153.3 million on September 30, 2026, which the company expects to fund operations and development through 2029.
Beyond AAV, InflaRx expects initial data from an investigator-initiated pilot study in atypical hemolytic uremic syndrome in the second half of 2027. It plans a pilot in IgA nephropathy starting in 2027, with early data in 2028. A pharmacokinetic bridging study in China is expected to report in the first half of 2027. Staidson's Phase 3 AAV trial of BDB-001 in China has data anticipated in the second half of 2028.
The company also named a seven-member advisory board of vasculitis and kidney-disease experts.
The first scheduled readout is the China pharmacokinetic bridging study, due in the first half of 2027.